Laman UtamaNZM • FRA
add
NOVONESIS NOVOZYMES B Unsponsored Denmark ADR
Tutup sebelumnya
€54.00
Julat hari
€53.00 - €53.00
Julat tahun
€49.40 - €66.00
Permodalan pasaran
166.09B DKK
Bilangan Purata
47.00
Nisbah P/E
-
Hasil dividen
-
Dalam berita
Kewangan
Penyata Pendapatan
Hasil
Pendapatan bersih
| (DKK) | Dis 2023info | Perubahan T/T |
|---|---|---|
Hasil | 4.60B | 1.63% |
Perbelanjaan pengendalian | 1.42B | — |
Pendapatan bersih | 698.00J | — |
Margin untung bersih | 15.16 | — |
Pendapatan bagi setiap syer | 3.06 | — |
EBITDA | 1.21B | — |
Kadar cukai berkesan | 24.70% | — |
Kunci Kira-kira
Jumlah aset
Jumlah liabiliti
| (DKK) | Dis 2023info | Perubahan T/T |
|---|---|---|
Pelaburan tunai dan jangka pendek | 1.12B | — |
Jumlah aset | 28.39B | — |
Jumlah liabiliti | 14.04B | — |
Jumlah ekuiti | 14.35B | — |
Syer tertunggak | 464.62J | — |
Harga kepada buku | 1.07 | — |
Pulangan pada aset | 9.38% | — |
Pulangan pada modal | 12.09% | — |
Aliran Tunai
Perubahan bersih dalam tunai
| (DKK) | Dis 2023info | Perubahan T/T |
|---|---|---|
Pendapatan bersih | 698.00J | — |
Tunai daripada operasi | 1.12B | — |
Tunai daripada pelaburan | -603.00J | — |
Tunai daripada pembiayaan | -555.00J | — |
Perubahan bersih dalam tunai | -59.00J | — |
Aliran tunai bebas | 718.50J | — |
Perihal
Novozymes A/S was a global biotechnology company headquartered in Bagsværd, outside of Copenhagen, Denmark. The company's focus was the research, development and production of industrial enzymes, microorganisms, and biopharmaceutical ingredients. The company merged with Chr. Hansen to form Novonesis in January 2024.
Prior to the merger, the company had operations around the world, including in China, India, Brazil, Argentina, United Kingdom, the United States, and Canada. Class B shares of its stock were listed on the NASDAQ OMX Nordic exchange. Wikipedia
CEO
Diasaskan
2000
Tapak web
Pekerja
10,582
